LITS

Lite Strategy Inc

1.27

Oct 09 • 3:59 PM ET +0.05 (4.10%)

1.26

Aftermarket • 4:15 PM ET -0.01 (-0.60%)

Healthcare Biotechnology USA Nano NASD

Peers: ABVC ALGS BOLD DARE EVAX NNVC TVRD GRCE INMB VERU

| Held by: VTI VXF IWC

Scroll to Statements

Index	-
Market Cap	38.62M
Enterprise Value	32.91M
Income	-71.15M
Sales	0.00M
Book/sh	1.28
Cash/sh	0.19
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	Nov 16, 2023
Dividend Gr. 3/5Y	- -
Payout	-
Employees	5
IPO	Dec 18, 2003

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	0.99
P/C	6.76
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	5.74
Current Ratio	5.74
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	Yes / Yes

EPS (ttm)	-1.99
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	24.47% 29.72%
Sales past 3/5Y	- -
EPS Y/Y TTM	16.97%
Sales Y/Y TTM	-
EPS Q/Q	6.77%
Sales Q/Q	-
Earnings	-
EPS/Sales Surpr.	- -

Insider Own	1.44%
Insider Trans	6.05%
Inst Own	19.68%
Inst Trans	0.01%
ROA	-233.37%
ROE	-243.02%
ROIC	-170.94%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-0.16%
SMA50	15.85%
SMA200	14.19%
Trades

Shs Outstand	32.41M
Shs Float	29.97M
Short Float	0.62%
Short Ratio	0.41
Short Interest	0.19M
52W High	2.97 -57.24%
52W Low	0.69 84.38%
Volatility	6.08% 9.29%
ATR (14)	0.11
RSI (14)	52.62
Beta	0.16
Rel Volume	1.18
Avg Volume	457.24K
Volume	539,931

Perf Week	-7.97%
Perf Month	19.81%
Perf Quarter	34.28%
Perf Half Y	9.48%
Perf YTD	-3.79%
Perf Year	-50.00%
Perf 3Y	-76.13%
Perf 5Y	-97.28%
Perf 10Y	-95.36%
Recom	2.33
Target Price	22.67
Prev Close	1.22
Price	1.27
Change %	4.10%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-23-24	Downgrade	Laidlaw	Buy → Hold
Mar-25-22	Downgrade	Wells Fargo	Overweight → Equal Weight	$13 → $2
Mar-25-22	Downgrade	Stifel	Buy → Hold	$6 → $2
Mar-25-22	Downgrade	Jefferies	Buy → Hold	$4 → $1
Feb-03-22	Initiated	Jefferies	Buy	$4
Sep-22-20	Initiated	Alliance Global Partners	Buy	$9
May-29-20	Initiated	SunTrust	Buy	$16
Dec-20-18	Initiated	H.C. Wainwright	Buy	$10
Dec-20-18	Initiated	H.C. Wainwright	Buy
Jul-27-18	Upgrade	Stifel	Hold → Buy	$2.50 → $7
Jul-13-18	Initiated	SunTrust	Buy	$12
Apr-18-16	Reiterated	Wedbush	Neutral	$3 → $2
Mar-23-15	Downgrade	ROTH Capital	Buy → Neutral	$14 → $2.50
Dec-18-14	Reiterated	ROTH Capital	Buy	$22 → $14
Oct-16-14	Reiterated	ROTH Capital	Buy	$20 → $22
Jul-08-14	Resumed	Brean Capital	Buy	$16
Oct-22-13	Reiterated	Stifel	Buy	$11 → $15
Apr-15-13	Initiated	Stifel	Buy	$11

Show Previous Ratings

Sep-29-26 08:30AM	Lite Strategy Reports Fiscal Year 2026 Financial Results (GlobeNewswire)
Sep-10-26 09:00AM	Lite Strategy to Present at the 28th Annual H.C. Wainwright Global Investment Conference in New York (GlobeNewswire)
Aug-12-26 12:07PM	Sellas Experimental Drug SLS009 Appears To Be Leading The CDK9 Race, Says Alliance Global Analyst Sees About 200% Upside Potential (Stocktwits)
Jul-30-26 08:30AM	Lite Strategy Repurchases 13% of Outstanding Shares Since December, Increasing Litecoin Backing Per Share (GlobeNewswire)
Jun-23-26 04:15AM	Can LitVM Bring Smart Contracts to Litecoin Without Changing Its Identity? (CCN)
08:30AM	Loading…
Jun-19-26 08:30AM	Lite Strategy to Attend Panel at Litecoin Foundation Summit in Amsterdam (GlobeNewswire)
Jun-18-26 08:30AM	Lite Strategy Leads Strategic Investment in LitVM (GlobeNewswire) -9.94%
07:45AM	Exclusive: Lite Strategy leads $1m investment in Litecoin Layer 2 platform LitVM (Investing.com)
May-13-26 08:30AM	Lite Strategy Reports Fiscal 2026 Third Quarter Results (GlobeNewswire) -5.60%
Feb-17-26 08:50AM	Lite Strategy Reports Fiscal 2026 Second Quarter Results (GlobeNewswire)
Nov-17-25 09:00AM	Lite Strategy Reports First Quarter Fiscal Year 2026 Results; Highlights Successful Launch of $100M Litecoin Treasury Strategy and Movement into Active Capital Market Operations (GlobeNewswire) -5.94%
Oct-29-25 09:00AM	Lite Strategy Announces $25M Share Repurchase Program, Signaling Shift From Initial Litecoin Accumulation to Active Capital Market Operations (GlobeNewswire) +7.77%
Oct-16-25 04:06PM	Lite Strategy Celebrates 14th Anniversary of Litecoin, Taps Institutional Signals Ahead of 2026 (GlobeNewswire) -13.15%
Sep-10-25 09:00AM	MEI Pharma, Inc. Rebrands as Lite Strategy, Inc., Adopts New NASDAQ Ticker LITS (Business Wire) +10.43%
Aug-28-25 04:23PM	Crypto Treasury Boom Triggers Insider Trading Concerns Fortune Report (Cryptonews) -6.54%
07:00AM	Loading…
07:00AM	Crypto hoarding brings a stock pop for small firmsand in some cases shows patterns of possible insider trading (Fortune)
Aug-25-25 09:47AM	Biotechs Turn to Digital Coins, Crypto to Boost Stock Prices (Bloomberg)
Aug-05-25 10:38AM	MEI Pharma Chooses Not Bitcoin, Not Ethereum, But Litecoin As Treasury Asset (Benzinga)
09:18AM	Litecoin Hits Five-Month High Amid ETF Optimism and $100M MEI Pharma Treasury (decrypt)
08:00AM	MEI Pharma Acquires Litecoin, Launches $100M Institutional Treasury Strategy with Charlie Lee and GSR Advising (Business Wire)
Jul-22-25 04:35PM	MEI Pharma Announces Closing of $100,000,000 Private Placement to Initiate Litecoin Treasury Strategy, Becoming First and Only Publicly Traded LTC Holder on a National Exchange (Business Wire) -9.62%
Jul-20-25 12:35AM	MEI Pharma (MEIP) Becomes the First and Only Publicly Traded LTC Holder on a National Exchange (Insider Monkey)
Jul-18-25 12:55PM	GSR Leads $100M Private Placement into Nasdaq-listed MEI Pharma to Launch First Institutional Litecoin Treasury Strategy Alongside Charlie Lee (etf.com) +31.56%
12:41PM	Crypto Market Value Tops $4 Trillion as Stablecoin Bill Passes (Bloomberg)
10:32AM	BC-Most Active Stocks (Associated Press Finance)
09:42AM	Litecoin Surges 10%; Will $100M Bet by Nasdaq-Listed Company Fuel a Larger Rally? (CoinDesk)
08:30AM	MEI Pharma Announces $100,000,000 Private Placement to Initiate Litecoin Treasury Strategy, Becoming First and Only Publicly Traded LTC Holder on a National Exchange (Business Wire)
May-13-25 04:05PM	MEI Pharma Reports Third Quarter Fiscal Year 2025 Cash Position (Business Wire) +6.22%
Mar-26-25 08:00AM	The Radoff-JEC Group Nominates Three Highly Qualified Candidates for Election to the Atea Pharmaceuticals Board of Directors (Business Wire)
Feb-12-25 04:12PM	MEI Pharma Reports Second Quarter Fiscal Year 2025 Cash Position (Business Wire)
04:05PM	Loading…
Nov-12-24 04:05PM	MEI Pharma Reports First Quarter Fiscal Year 2025 Cash Position (Business Wire)
Sep-19-24 04:01PM	MEI Pharma Reports Fiscal Year End 2024 Cash Position (Business Wire) -5.10%
Aug-12-24 08:30AM	MEI Pharma Engages Oppenheimer & Co. Inc. to Assist in Evaluating Strategic Alternatives (Business Wire)
Jul-22-24 08:30AM	MEI Pharma to Consider Strategic Alternatives (Business Wire) +21.33%
Jul-01-24 02:18PM	7 Undervalued Biotech Stocks to Buy for Big-Time Returns (InvestorPlace)
May-09-24 10:57PM	MEIP Stock Earnings: MEI Pharma Beats EPS for Q3 2024 (InvestorPlace)
04:02PM	MEI Pharma Reports Third Quarter Fiscal Year 2024 Results and Operational Highlights (Business Wire)
Apr-11-24 08:02AM	MEI Pharma Board of Directors Aligns on Strategy to Advance Voruciclib and ME-344 (Business Wire)
08:00AM	MEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin) in Relapsed Metastatic Colorectal Cancer Patients (Business Wire)
Apr-10-24 08:00AM	MEI Pharma to Present at the Stifel 2024 Virtual Targeted Oncology Forum (Business Wire)
Mar-26-24 08:00AM	MEI Pharma Reports Update from Clinical Study Evaluating Oral CDK9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid Leukemia (Business Wire)
Mar-09-24 01:09PM	12 Most Undervalued Biotech Stocks To Buy According To Hedge Funds (Insider Monkey)
Feb-13-24 06:15PM	MEI Pharma, Inc. (MEIP) Reports Q2 Loss, Misses Revenue Estimates (Zacks) -5.32%
05:05PM	MEI Pharma Reports Second Quarter Fiscal Year 2024 Results and Operational Highlights (Business Wire)
Feb-08-24 06:48AM	Is MEI Pharma (MEIP) Attractively Priced? (Insider Monkey)
Jan-16-24 05:00PM	MEI Pharma to Present Design of Ongoing Clinical Study Evaluating ME-344 at ASCO GI Cancers Symposium 2024 (Business Wire) -11.55%
Dec-11-23 12:00PM	MEI Pharma Reports Clinical Data on Oral CDK9 Inhibitor Voruciclib at ASH2023 (Business Wire)
Nov-27-23 10:33AM	11 Cheapest Stocks With Biggest Upside (Insider Monkey) +6.61%
Nov-09-23 04:05PM	MEI Pharma Reports First Quarter Fiscal Year 2024 Results and Operational Highlights (Business Wire)
Nov-08-23 08:00AM	MEI Pharma to Present at the Stifel 2023 Healthcare Conference (Business Wire)
Nov-06-23 04:57PM	MEI Pharma Declares Special Cash Dividend of $1.75 Per Share of Common Stock (Business Wire) +6.57%
Nov-02-23 11:23AM	Corcept (CORT) Beats on Q3 Earnings, Raises '23 Sales View (Zacks)
09:00AM	MEI Pharma Announces Acceptance of Abstract for Presentation at ASH 2023 (Business Wire)
Nov-01-23 12:03PM	Amarin (AMRN) Q3 Earnings and Revenues Surpass Estimates (Zacks)
09:00AM	MEI Pharma Enters into Agreement with Anson Funds and Cable Car Capital (Business Wire)
Oct-20-23 11:43AM	BEAM to Reprioritize Portfolio, Slash Jobs, Shares Tank (Zacks)
Oct-18-23 11:13AM	Lisata's (LSTA) Lead Cancer Drug Gets EC's Orphan Tag, Stock Up (Zacks)
Oct-17-23 05:33PM	MEI Pharma Recommends Stockholders Not to Consent (Business Wire)
11:47AM	Editas (EDIT) Gets FDA's RMAT Tag for Gene Therapy to Treat SCD (Zacks)
11:30AM	AstraZeneca's (AZN) Tagrisso Combo Gets FDA's Priority Review (Zacks)
Oct-16-23 12:53PM	Catalyst (CPRX) Seeks to Increase Maximum Daily Dose for Firdapse (Zacks)
Oct-10-23 10:54AM	Anson and Cable Car Send Letter to MEI Pharma Stockholders (GlobeNewswire)
Oct-02-23 06:00AM	MEI Pharma Adopts Limited-Duration Stockholder Rights Plan (Business Wire)
Sep-29-23 12:00PM	All You Need to Know About MEI Pharma, Inc. (MEIP) Rating Upgrade to Strong Buy (Zacks)
Sep-28-23 05:00PM	MEI Pharma Issues Statement Regarding Anson and Cable Cars Opportunistic Actions (Business Wire)
Sep-27-23 09:28AM	Q4 2023 MEI Pharma Inc Earnings Call (Thomson Reuters StreetEvents)
09:12AM	MEI Pharma, Inc. (NASDAQ:MEIP) Q4 2023 Earnings Call Transcript (Insider Monkey)
Sep-26-23 04:02PM	MEI Pharma Reports Fiscal Year 2023 Results and Operational Highlights (Business Wire)
05:03AM	Anson Funds Management LP Acquires Shares in MEI Pharma Inc (GuruFocus.com)
Sep-23-23 05:03AM	Anson Funds Management LP Acquires Additional Shares in MEI Pharma Inc (GuruFocus.com)
Sep-21-23 08:00AM	MEI Pharma to Report 2023 Fiscal Year End Financial Results and Provide Corporate Overview on September 26, 2023 (Business Wire) +5.92%
Sep-18-23 08:00AM	MEI Pharma Confirms Receipt of Director Nominations From Anson and Cable Car (Business Wire)
Sep-05-23 12:17PM	Three execs leave Infinity Pharmaceuticals after failed merger, layoffs (American City Business Journals)
Aug-16-23 08:00AM	MEI Pharma Announces First Patient Dosed in Clinical Study Evaluating ME-344 Plus Bevacizumab (AVASTIN®) in Patients with Previously Treated Metastatic Colorectal Cancer (Business Wire)
Jul-26-23 01:47PM	Cambridge biotech cuts most staffers after merger falls apart (American City Business Journals)
Jul-23-23 02:30PM	MEI Pharma Announces Results of Special Meeting of Stockholders (Business Wire)
Jul-19-23 08:00AM	MEI Pharma Reminds Shareholders to Vote Today FOR the Infinity Transaction (Business Wire)
Jul-18-23 09:00AM	MEI Pharma Responds to Anson and Cable Car (Business Wire)
Jul-17-23 09:17AM	Anson and Cable Car File Preliminary Consent Materials to Remove Entire Board of Directors at MEI Pharma, Inc. (GlobeNewswire)
08:00AM	MEI Pharma Encourages Shareholders to Vote FOR the Infinity Transaction (Business Wire)
Jul-13-23 04:05PM	MEI Pharma Postpones Special Meeting of Shareholders (Business Wire) +10.22%
Jul-11-23 08:00AM	MEI Pharma Provides Final Reminder to Shareholders to Vote Today FOR the Merger With Infinity Pharmaceuticals (Business Wire)
Jul-07-23 08:00AM	MEI Pharma Reminds Shareholders to Vote FOR the Merger with Infinity Pharmaceuticals (Business Wire)
Jul-05-23 08:00AM	MEI Pharma Highlights Recommendation by Leading Independent Proxy Advisory Firm ISS to Vote "FOR" Pending Transaction with Infinity Pharmaceuticals (Business Wire)
Jun-29-23 08:00AM	MEI Pharma Mails Letter to Shareholders Reiterating Value Creating Potential of Proposed Transaction with Infinity Pharmaceuticals (Business Wire)
Jun-27-23 05:15PM	MEI Pharma Responds to Anson and Cable Car (Business Wire)
09:20AM	Anson Funds and Cable Car Capital Issue Statement Regarding the Inferior Proposed Transaction between MEI Pharma and Infinity Pharmaceuticals (GlobeNewswire)
Jun-15-23 12:08PM	MEI Pharma and Infinity Pharmaceuticals Host Video Webcast Providing Overview and Update on Pending Merger to Advance Three Promising Clinical Oncology Candidates (Business Wire)
Jun-13-23 08:00AM	MEI Pharma Announces Planned Departure of Chief Financial Officer Brian Drazba and Appointment of Justin File as Successor (Business Wire)
Jun-02-23 08:00AM	MEI Pharma Announces Planned Departure of CEO Daniel P. Gold, Ph.D. and Appointment of David M. Urso as Successor (Business Wire)
Jun-01-23 04:22PM	Anson Funds and Cable Car Capital Issue Statement Regarding MEI Pharmas Rejection of Their Acquisition Proposal (GlobeNewswire)
08:00AM	MEI Pharma Board of Directors Rejects Unsolicited Proposal (Business Wire)
May-30-23 05:40PM	MEI Pharma Confirms Receipt of Unsolicited Acquisition Proposal (Business Wire) +6.94%
May-23-23 04:49PM	Clinical Triumph: MEI Pharma's Voruciclib Demonstrates Encouraging Activity in AML Patients (Benzinga)
08:00AM	MEI Pharma Announces Update of Ongoing Phase 1 Study Evaluating Oral CDK9 Inhibitor Voruciclib Alone and in Combination with Venetoclax in Patients with Acute Myeloid Leukemia or B-Cell Malignancies (Business Wire)
May-11-23 05:35PM	MEI Pharma, Inc. (MEIP) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:05PM	MEI Pharma Reports Third Quarter Fiscal Year 2023 Results and Operational Highlights (Business Wire)
May-09-23 08:35AM	Assertio (ASRT) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
Apr-18-23 03:31PM	Lacklustre Performance Is Driving MEI Pharma, Inc.'s (NASDAQ:MEIP) Low P/S (Simply Wall St.)
Apr-14-23 04:15PM	MEI Pharma Announces 1-for-20 Reverse Stock Split (Business Wire)

Lite Strategy, Inc. is a pharmaceutical company, which engages in the development of pharmaceutical compounds. Its programs include Voruciclib and ME-344. The company was founded on December 1, 2000, and is headquartered in San Diego, CA.

Chief People OfficerMs. Anne Frese

Strategic AdvisorDr. Robert D. Mass M.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Flynn James P	Director	Jun 24 '26	Buy	0.86	25,000	21,388	125,000	Jun 25 04:30 PM
Schornstein Alexander	10% Owner	Dec 18 '25	Sale	1.37	690,611	946,137	3,674,862	Dec 22 04:15 PM
Flynn James P	Director	Dec 19 '25	Buy	1.40	70,000	97,699	100,000	Dec 22 04:00 PM
Flynn James P	Director	Nov 19 '25	Buy	1.88	12,100	22,777	30,000	Nov 20 04:00 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

LITS

Lite Strategy Inc

Upgrade your Finviz experience